Related Articles
Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene